Pacer Advisors
RYTM icon

Pacer Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Pacer Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-413
Closed -$17K – 2678
2024
Q2 		$17K Sell
413
-605
-59% -$24.1K ﹤0.01% 3459
2024
Q1 		$44.1K Buy
+1,018
New +$44.6K ﹤0.01% 3218
2021
Q2 		– Sell
-2,845
Closed -$61K – 1538
2021
Q1 		$61K Buy
2,845
+1,462
+106% +$42.4K ﹤0.01% 1415
2020
Q4 		$41K Buy
1,383
+432
+45% +$11K ﹤0.01% 1435
2020
Q3 		$21K Buy
+951
New +$21.8K ﹤0.01% 1354
2018
Q4 		– Sell
-1,608
Closed -$47K – 945
2018
Q3 		$47K Buy
+1,608
New +$50.8K ﹤0.01% 1143

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors's RYTM Position: Q3 2024 in Review

Pacer Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2024, closing a stake of 413 shares — an estimated $17K sold.

Pacer Advisors first reported a position in RYTM in Q3 2018 and held it in 6 quarters. The position peaked at $61K in Q1 2021. 176 funds tracked by Wall St. Rank hold RYTM as of Q3 2024.

  • Pacer Advisors reported no remaining Rhythm Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 413 Rhythm Pharmaceuticals shares in Q3 2024, an estimated $17K.
  • Pacer Advisors first reported a position in Rhythm Pharmaceuticals in Q3 2018 and held it in 6 quarters.
  • Pacer Advisors's Rhythm Pharmaceuticals position peaked at $61K in Q1 2021.
  • 176 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.